TrianglePUBLICATIONS · 39033770
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Haematol
- Publication date
- 2024 Sep
- First author
- Wierda WG
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Wierda WG
- type
- Author
- name
- Shah NN
- type
- Author
- name
- Cheah CY
- type
- Author
- name
- Lewis D
- type
- Author
- name
- Hoffmann MS
- type
- Author
- name
- Coombs CC
- type
- Author
- name
- Lamanna N
- type
- Author
- name
- Ma S
- type
- Author
- name
- Jagadeesh D
- type
- Author
- name
- Munir T
- type
- Author
- name
- Wang Y
- type
- Author
- name
- Eyre TA
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Wierda WG
- type
- Author
- name
- Shah NN
- type
- Author
- name
- Cheah CY
- type
- Author
- name
- Lewis D
- type
- Author
- name
- Hoffmann MS
- type
- Author
- name
- Coombs CC
- type
- Author
- name
- Lamanna N
- type
- Author
- name
- Ma S
- type
- Author
- name
- Jagadeesh D
- type
- Author
- name
- Munir T
- type
- Author
- name
- Wang Y
- type
- Author
- name
- Eyre TA
- type
- Author
- bibliography ids
- nci-bib-d54c26c8c5d4344a39e1bf90
- book metadata
- content sha256
- d5859e42950ecd1ad163189700581e107c33988f1e132855ceaa11618c146ff1
- document type
- citation
- dois
- 10.1016/S2352-3026(24)00172-8
- electronic publication date
- display
- 2024 Jul 18
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:39033770
- immutable id
- pubmed:39033770@d5859e42950ecd1ad163189700581e107c33988f1e132855ceaa11618c146ff1
- journal
- abbreviation
- Lancet Haematol
- issn electronic
- 2352-3026
- issn print
- Source null
- issue
- 9
- name
- The Lancet. Haematology
- nlm unique id
- 101643584
- pages
- e682-e692
- volume
- 11
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 39033770
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- ff3ac00b00fcae93d1d16de12b3a3fb9bc9e5bfd67c5e2f4f8c8444075cce483
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Sep
- precision
- month
- year
- 2024
- publication types
- Journal Article
- Clinical Trial, Phase I
- Clinical Trial, Phase II
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
Preserved source evidence · Not medical advice